Your privacy is very important to us.When you visit our website,please agree to the use of all cookies.For more information about personal data processing,please go to Privacy Statement

  • b3banner01.jpg b3banner01ph.jpg

    Milestone

Nuance Story

2022

2021

2020

2019

2018

2015

2014

2022

Licensed in First-in-Class MVA-BN-RSV Vaccine from Bavarian Nordic

Licensed in allergy alleviation / virus prevention nasal spray Bentrio™ from Altamira Therapeutics

shouyeOurTransformativeJourney-958.png

2021

Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma

Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma

Acquired Sino Health (Yinglian) with access to 3 commercial products in emergency care and a GSP license

shouyeOurTransformativeJourney-761.png

2020

Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum

Raised US$ 181 million Series D equity funding

shouyeOurTransformativeJourney-337.png

2019

Acquired NIFEREX Iron Polysaccharide Complex Capsules

shouyeOurTransformativeJourney-651.png

2018

Established exclusive partnership with Aerogen Pharma on nebulizer device

Accumulatively raised US$ 80 million equity funding

shouyeOurTransformativeJourney-373.png

2015

Established Commercial Platform for footprint in China

shouyeOurTransformativeJourney-58.png

2014

Mr. Mark Lotter founded Nuance Pharma in Shanghai

shouyeOurTransformativeJourney-129.png

CONTACT

Suite 639, East Tower, No 1376 Nan Jing West Road, Shanghai. 200040

Copyright 2022 NUANCE BIOTECH INC reserved. 沪ICP备17029781号-4